1. Volume 59, Issue 2, Pages 258-263 (February 2011)
Is There a Need to Further Subclassify pT2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version? 
Sandra Waalkes, Frank Becker, Andres J. Schrader, Martin Janssen, Gerd Wegener, Axel S. Merseburger, Mark Schrader, Rainer Hofmann, Michael Stöckle, Markus A. Kuczyk 
European Urology 
Volume 59, Issue 2, Pages (February 2011)
DOI: /j.eururo
Copyright © 2010 European Association of Urology Terms and Conditions

2. Fig. 1
Clinical outcome did not correlate with pT2 subcategories (Kaplan-Meier method). (a) The 5-yr cancer-specific survival (CSS) rate for the whole cohort of pT2 patients was 78.0% and did not differ significantly between pT2a and pT2b tumours (79.0% vs 74.1%; p=0.38; log-rank test). (b) For the subgroup of patients without regional lymph node or distant metastases (N0/M0), the 5-yr CSS rates were 85.2% and 80.1% for stage pT2a and pT2b, respectively (p=0.10; log-rank test).
European Urology  , DOI: ( /j.eururo )
Copyright © 2010 European Association of Urology Terms and Conditions